CureVac Posts Wider Loss In Q4

CureVac N.V. (CVAC) reported loss before taxes of 57.3 million euros for three months ended December 31, 2020, compared to a loss of 35.9 million euros, prior year. Operating loss was 46.6 million euros, compared to a loss of 35.1 million euros. The company said the increase in fourth quarter operating loss was mainly driven by higher research and development costs, primarily due to high costs for CVnCoV R&D activities, including research material manufacturing expenses.

Fourth quarter revenue was 6.0 million euros, a decline of 11.8% from 6.8 million euros, last year.

CureVac currently expects completing data submission in time to file for conditional approval of CVnCoV, the company's COVID-19 vaccine candidate, in second quarter, 2021. The company initiated a rolling submission with the European Medicines Agency on February 12, 2021.

Shares of CureVac were up 5% in pre-market trade on Thursday.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Southwest Airlines' flights across the United States were delayed for hours on Monday evening due to technical issue in a weather information system by a third-party weather data provider. The airline later resumed flight operations after solving the issue, but there were delays. The United Kingdom's Competition and Markets Authority or CMA announced Tuesday that it has launched a market study into mobile ecosystems of technology giants Apple Inc. (AAPL) and Google, Inc. (GOOG) over concerns they have market power which is harming users and other businesses. The CMA is taking... Eli Lilly and Co. (LLY) announced Tuesday that it will conduct a head-to-head study comparing once-monthly injectable Emgality (galcanezumab-gnlm) with Nurtec ODT (rimegepant), an orally disintegrating tablet patients take every other day. This study will help to advance the science of migraine treatment...
Follow RTT